파상풍 톡소이드 백신 시장 규모, 점유율, 동향 분석 보고서 : 백신별, 질환별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Tetanus Toxoid Vaccine Market Growth & Trends:

The global tetanus toxoid vaccine market size is anticipated to reach USD 8.09 billion by 2030 and is expected to expand at a CAGR of 5.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The tetanus toxoid vaccine industry is witnessing significant growth due to the increasing focus on immunization programs and rising awareness about vaccine-preventable diseases. Tetanus, a severe bacterial infection affecting the nervous system, remains a global health concern, particularly in regions with low vaccination coverage. The expanding adoption of vaccination drives and improved healthcare infrastructure are key factors propelling market expansion.

A major contributor to market growth is the availability of combination vaccines, which provide broader protection against multiple diseases. The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is widely administered in pediatric immunization schedules, ensuring early protection against these serious infections. Similarly, the Diphtheria and Tetanus (DT) vaccine is essential for individuals who cannot receive the pertussis component, supporting alternative immunization options. Additionally, the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine plays a crucial role in booster doses for adolescents and adults, reinforcing long-term immunity and reducing disease transmission.

The market is further strengthened by the classification of vaccines based on target diseases. While Tetanus-focused vaccines remain central to immunization strategies, the integration of Diphtheria protection enhances overall effectiveness. The inclusion of other vaccine formulations tailored for specific patient groups contributes to a more comprehensive immunization approach, expanding accessibility across diverse populations.

Distribution channels play a pivotal role in ensuring widespread vaccine availability. Hospitals serve as primary immunization centers, offering immediate access to tetanus toxoid vaccines, especially in emergency wound management cases. Specialty clinics contribute significantly by providing routine vaccinations, particularly for high-risk groups such as pregnant women and travelers. Additionally, other healthcare providers, including community health centers and pharmacies, are expanding their role in vaccination services, enhancing market penetration.

With continuous advancements in vaccine formulations and increasing governmental efforts to improve immunization rates, the market is poised for steady growth in the coming years.

Tetanus Toxoid Vaccine Market Report Highlights:

• The vaccine segment of Diphtheria, Tetanus, and Pertussis (DTaP) held the largest share of the tetanus toxoid vaccine industry in 2024. This dominance can be attributed to the widespread adoption of DTaP in routine immunization programs, offering comprehensive protection against multiple bacterial infections, particularly in pediatric and booster vaccination schedules.
• In the disease segment, tetanus remained the dominant contributor to market growth in 2024. The high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as newborns and trauma patients, has driven demand for effective vaccination strategies, reinforcing the importance of tetanus toxoid immunization.
• In end-use segment, hospitals dominated the market in 2024. Hospitals play a crucial role in vaccination programs, emergency prophylaxis, and post-exposure tetanus management, ensuring timely administration of vaccines, especially in cases of injuries and wound care. The availability of trained healthcare professionals further supports the efficiency of hospital-based immunization.
• North America led the market in 2024, driven by advanced healthcare infrastructure, well-established immunization programs, and increasing awareness about vaccine-preventable diseases. Favorable government policies and initiatives promoting routine and booster vaccinations have further contributed to regional market dominance.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Tetanus Toxoid Vaccine Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing government immunization programs
    • 3.3.1.2. Rising awareness & preventive healthcare
    • 3.3.1.3. Increasing birth rates & pediatric vaccination
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Vaccine shortages & supply chain issues
    • 3.3.2.2. Low awareness in developing regions
• 3.4. Tetanus Toxoid Vaccine Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Tetanus Toxoid Vaccine Market: By Vaccine Estimates & Trend Analysis

• 4.1. Tetanus Toxoid Vaccine Market: Vaccine Segment Dashboard
• 4.2. Tetanus Toxoid Vaccine Market: By Vaccine Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Diphtheria, Tetanus, and Pertussis (DTaP)
  • 4.3.1. Diphtheria, Tetanus, and Pertussis (DTaP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Diphtheria and Tetanus (DT)
  • 4.4.1. Diphtheria and Tetanus (DT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Tetanus, Diphtheria and Pertussis (Tdap)
  • 4.5.1. Tetanus, Diphtheria and Pertussis (Tdap) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tetanus Toxoid Vaccine Market: Disease Estimates & Trend Analysis

• 5.1. Tetanus Toxoid Vaccine Market: Disease Segment Dashboard
• 5.2. Tetanus Toxoid Vaccine Market: By Disease Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Tetanus
  • 5.3.1. Tetanus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Diphtheria
  • 5.4.1. Diphtheria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tetanus Toxoid Vaccine Market: End Use Estimates & Trend Analysis

• 6.1. Tetanus Toxoid Vaccine Market: End Use Segment Dashboard
• 6.2. Tetanus Toxoid Vaccine Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Specialty Clinics
  • 6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tetanus Toxoid Vaccine Market: Regional Estimates & Trend Analysis

• 7.1. Tetanus Toxoid Vaccine Market Share, By Region, 2024 & 2030, USD Million
• 7.2. North America
  • 7.2.1. North America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018- 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Norway
    • 7.3.8.1. Norway Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Sweden
    • 7.3.9.1. Sweden Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. Kuwait
    • 7.6.4.1. Kuwait Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Africa
    • 7.6.5.1. South Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Pfizer, Inc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. GSK plc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Sanofi
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Merck & Co., Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Grifols, S.A.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Emergent BioSolutions Inc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Virbac
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Zoetis Services LLC
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Ceva.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Abbott
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives